Department of Oral and Maxillofacial Surgery, Hirosaki University Graduate School of Medicine, 5-Zaifu-cho, Hirosaki 036-8562, Japan.
Oral Oncol. 2010 Dec;46(12):860-3. doi: 10.1016/j.oraloncology.2010.10.001. Epub 2010 Nov 2.
Cisplatin-based, superselective, intra-arterial chemotherapy concurrent with radiotherapy (SSIACRT) has gained wide acceptance as a common/curative treatment for advanced head and neck cancer. We combined nedaplatin (CDGP) with docetaxel (DOC) as a new combination in SSIACRT for advanced oral squamous cell carcinoma in 2003. Twenty-two patients with advanced oral cancer were treated by radiotherapy (66 Gy) concurrent with superselective intra-arterial DOC (40 mg/body) and CDGP (80 mg/m²) infusion between 2003 and 2009. Complete response was achieved in 18 (81.8%) of the 22 patients. Of the 17 patients with positive neck disease, 16 (94%) were assessed as disease-free. The 5-year overall survival rate was 78.5%, and the major adverse effects were leukocytopenia and mucositis. Five patients (22.7%) developed distant metastases post-treatment. These results indicate that intra-arterial docetaxel-nedaplatin infusion concurrent with radiotherapy is efficacious for advanced oral cancer. The side effects are easily manageable, and the most important outcome of the treatment is the preservation of patients' quality of life (QOL) and improved prognosis.
顺铂为基础的超选择性、动脉内化疗联合放疗（SSIACRT）已被广泛接受为治疗晚期头颈部癌症的常用/根治性治疗方法。我们于 2003 年将奈达铂（CDGP）与多西他赛（DOC）联合作为 SSIACRT 治疗晚期口腔鳞状细胞癌的新组合。2003 年至 2009 年间，22 例晚期口腔癌患者接受了放疗（66Gy）联合超选择性动脉内 DOC（40mg/体）和 CDGP（80mg/m²）输注。22 例患者中 18 例（81.8%）达到完全缓解。17 例颈部阳性疾病患者中，16 例（94%）无疾病。5 年总生存率为 78.5%，主要不良反应为白细胞减少和粘膜炎。5 例患者（22.7%）治疗后发生远处转移。这些结果表明，动脉内多西他赛-奈达铂输注联合放疗对晚期口腔癌有效。副作用易于处理，治疗的最重要结果是患者生活质量（QOL）的改善和预后的提高。
